MCHP · Microchip Technology Incorporated
Is the margin reset already overdone?
Executive Thesis
BUY: the post-earnings dislocation values Microchip at roughly 15x our conservative FY2028 EPS despite a broad cyclical recovery and substantial operating leverage. Its embedded-control franchise combines sticky designs, premium pricing, long product lives and emerging data-center, defense and edge-AI optionality. The forensic caveats are material: September margins were flattered by $53 million of infrequent revenue, inventory remains elevated, leverage constrains repurchases and supplier inflation has forced a margin reset. Accumulate below $70, targeting $85 while sizing for semiconductor-cycle, execution and tax-contingency risk.
Key Actionable Findings
Click any finding to interrogate with Andy ↗Frequently Asked Questions: MCHP
What is L2 Capital's investment rating and price target for MCHP?
L2 Capital currently maintains an institutional rating of BUY on Microchip Technology Incorporated (MCHP) with a 12-month target price of $85.00 (implied return: +31.1%), backed by High conviction.
What is the core investment thesis for MCHP?
BUY: the post-earnings dislocation values Microchip at roughly 15x our conservative FY2028 EPS despite a broad cyclical recovery and substantial operating leverage. Its embedded-control franchise combines sticky designs, premium pricing, long product lives and emerging data-center, defense and edge-AI optionality. The forensic caveats are material: September margins were flattered by $53 million of infrequent revenue, inventory remains elevated, leverage constrains repurchases and supplier inflation has forced a margin reset. Accumulate below $70, targeting $85 while sizing for semiconductor-cycle, execution and tax-contingency risk.
What are MCHP's latest audited financial fundamentals?
According to audited SEC EDGAR filings, Microchip Technology Incorporated reported total revenue of $4.71B (+7.1% YoY), Gross Margin of 57.7%, Free Cash Flow of $871.0M, and Net Debt of $5.26B.
What key risks and catalyst factors should investors monitor for MCHP?
- September-quarter sales rose 9.2% sequentially, while underlying December product revenue is guided above normal seasonality after removing infrequent items.
- Management reset near-term non-GAAP gross margin to 64%-65%, but maintained its 65%/25%/40% long-term model.
- Book-to-bill remained well above one, backlog increased and PCIe Gen6 switch/retimer design wins reached 24, yet supply constraints delay monetization.